Get started
Author

Matteo Landi

Observed names: LANDI, MATTEO, M. Landi, M.B. Landi
ORCID: 0000-0003-3789-5840
Observed ORCID: 0000-0003-3789-5840
OpenAlex ID: A5043936629
The Role of Artificial Intelligence on Tumor Boards: Perspectives from Surgeons, Medical Oncologists and Radiation Oncologists
2024 · Valerio Nardone, Federica Marmorino, et al. · Current Oncology · 61
PDF
Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
2023 · Claire Gallois, Matteo Landi, et al. · Clinical Cancer Research · 33
PDF
Transcriptomic signatures of MSI-high metastatic colorectal cancer to predict efficacy of immune checkpoint inhibitors.
2023 · Claire Gallois, Matteo Landi, et al. · Journal of Clinical Oncology · 3
Total neoadjuvant treatment, non-operative management and radiotherapy-free strategies: New approaches for the management of proficient mismatch repair/microsatellite stable locally advanced rectal cancer. A narrative review and evidence-based algorithm
2025 · Roberto Moretto, Chiara Boccaccio, et al. · European Journal of Cancer · 2
71P Early- versus late-onset RAS wild-type (RASWT) metastatic colorectal cancer (mCRC) patients receiving first-line (1L) anti-EGFR therapy: A pooled ctDNA analysis of three clinical trials
2026 · V. Martelli, J. Vidal Barrull, et al. · Annals of Oncology · 1
PDF
Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
2026 · Roberto Moretto, Vittorio Studiale, et al. · Clinical Cancer Research · 1
Data from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
2023 · Claire Gallois, Matteo Landi, et al. · 1
Prognostic Modeling Integrating RAS and SMAD4 Status in Patients with BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer
2026 · Vincenzo Nasca, Gabriele Tinè, et al. · Cancer Research Communications
PDF
Figure S2 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
2026 · Roberto Moretto, Vittorio Studiale, et al.
Figure S3 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
2026 · Roberto Moretto, Vittorio Studiale, et al.
Figure S5 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
2026 · Roberto Moretto, Vittorio Studiale, et al.
Figure S1 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
2026 · Roberto Moretto, Vittorio Studiale, et al.
Table S2 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
2026 · Roberto Moretto, Vittorio Studiale, et al.
Data from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
2026 · Roberto Moretto, Vittorio Studiale, et al.
Table S3 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
2026 · Roberto Moretto, Vittorio Studiale, et al.
Table S1 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
2026 · Roberto Moretto, Vittorio Studiale, et al.
Figure S4 from Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment
2026 · Roberto Moretto, Vittorio Studiale, et al.
4RO Chemotherapy (CT) plus anti-EGFR retreatment versus CT switch plus anti-VEGF/R after progression in pMMR/MSS, RAS/BRAF wild-type metastatic colorectal cancer (mCRC): Individual patient data analysis of 5 randomized trials (RCTs)
2026 · V. Studiale, M.M. Germani, et al. · Annals of Oncology
PDF
67P Clinical and molecular predictors of early progression in metastatic colorectal cancer: Pooled analysis of the TRIBE and TRIBE2 studies
2026 · M.G. Polito, M.B. Landi, et al. · Annals of Oncology
PDF
Distinct outcome patterns according to RAS and BRAF status in MSI-H/dMMR mCRC treated with immune checkpoint inhibitors: A systematic review and meta-analysis
2026 · Andrea Pretta, Riccardo Giampieri, et al. · Cancer Treatment Reviews
Plasma-TMB (pTMB) and circulating tumor fraction (ctF) dynamics as biomarkers of benefit from the addition of atezolizumab to first-line FOLFOXIRI/bevacizumab in metastatic colorectal cancer (mCRC): A translational analysis of the AtezoTRIBE study.
2026 · Veronica Conca, Michelle Ting-Lin, et al. · Journal of Clinical Oncology
Neoadjuvant (NA) chemoradiotherapy (CTRT) plus avelumab (Ave) in locally advanced rectal cancer (LARC): 4-year outcomes of the phase II AVANA trial and their association with computational pathology.
2026 · Giovanni Trovato, Maria Bensi, et al. · Journal of Clinical Oncology
Sotorasib plus panitumumab and 5-fluorouracil in first-line treatment of patients with unresectable KRAS G12C mutated colorectal cancer unfit for a doublet/triplet chemotherapy: ENGIC 01 – PRODIGE 107 – FFCD 2306 – COLOSOTO trial
2026 · Adrien Grancher, Matteo Landi, et al. · Digestive and Liver Disease
Comprehensive genomic profiling in solid tumours: Navigating promise, challenges, and pathways to clinical integration
2026 · Vittorio Studiale, Ada Taravella, et al. · Cancer Treatment Reviews
Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study
2026 · G. Trovato, M. Carullo, et al. · ESMO Gastrointestinal Oncology
PDF
Works count: 72
Citation count: 102
H-index: 3
I10-index: 2
Year
Topic
Type